Natco Pharma has informed that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business: Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December 2025 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time (Listing Regulations) along with Limited Review Report of the Statutory Auditors. It has enclosed a copy of the same for information; Declared third interim dividend of Rs 1.50 (75%) each per equity share of Rs 2 each for the financial year 2025-26. The date for taking on record of its shareholders eligible for the purpose of payment of third interim dividend i.e., record date is fixed as Wednesday, the 18th February, 2026. The payment of said interim dividend will start from 26th February, 2026; and etc.

The above information is a part of company’s filings submitted to BSE.